Inclusion of phase III clinical trial costs in health economic evaluations
Abstract Introduction Protocol-driven trial activities contribute to the utility gain demonstrated in the phase III clinical trial of a new drug. If this utility gain cannot be distinguished from the effects of the new drug itself, protocol-driven trial costs cannot be easily dismissed for consisten...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
BMC,
2024-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!